Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Orphanet Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol SLC6A3 contributors: mct - updated : 20-04-2020
HGNC name solute carrier family 6 (neurotransmitter transporter, dopamine), member 3
HGNC id 11049
ASSOCIATED DISORDERS
corresponding disease(s) ADHD , PKDYS1
Other morbid association(s)
TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
tumoral   amplification    
in early stages of non-small cell lung cancer (Kang 2008)
constitutional   deletion    
promoted a previously unobserved conformation of the intracellular gate of the transporter, likely representing the rate-limiting step of the transport process
tumoral     --over  
in Clear Cell Renal Cell Carcinoma
Susceptibility
  • to attention deficit hyperactivity disorder with preferential transmission of paternal alleles
  • to bipolar affective disorder, psychiatric disorders of children and cigarette smoking, alcoholism, cocaine-induced paranoia
  • to migraine with aura
  • to hypertension
  • Variant & Polymorphism repeat
  • Int8 VNTR is associated with cocaine dependence
  • 10 repeat allele of the 3' UTR VNTR show a significant main effect on relative SLC6A3 expression
  • SLC6A3 40bo VNTR showed an association with the peak tic severity in Tourette Syndrome (patients with one copy of the 9-repeat allele had significantly more severe symptoms than individuals with the homozygous 10/10 genotype)
  • SLC6A3 genotype influence these attentional/cognitive functions which deficits are not the key symptoms in ADHD
  • SLC6A3-MS8 (rs3836790), having an 8/6-repeat allele, which was only detected in hypertensive cases, was associated with hypertension
  • Candidate gene candidate gene for Parkinson's disease (PD) on the basis of its critical role in dopaminergic neurotransmission
    Marker
  • potential epigenetic biomarker with value in the early diagnosis and management of neurodevelopmental diseases in newborns
  • novel biomarker that is highly specific for ccRCC (Clear Cell Renal Cell Carcinoma)
  • Therapy target
  • target of psychomotor stimulants such as amphetamines or cocaine
  • is a target for psychoactive drugs (Dreher 2009)
  • SystemTypeDisorderPubmed
    psychiatry  
    targeting SLC6A3 activity might be a very attractive approach to tackle affective disorders
    ANIMAL & CELL MODELS
  • mice lacking SLC6A3 protein have elevated dopaminergic tone and are hyperactive, with a decrease in locomotion in response to psychostimulants
  • SLC6A3 null mice with pharmacologic inhibition of tyrosine hydroxylase demonstrated severe akinesia, rigidity, tremor and psotis similar to behaviors observed in patients with Parkinson Disease. L-dopa temporarily restored locomotion and amphetamines deriatives showed effectiveness in reducing motor abnormalities